Fehm Tanja N, Welslau Manfred, Müller Volkmar, Lüftner Diana, Schütz Florian, Fasching Peter A, Janni Wolfgang, Thomssen Christoph, Witzel Isabell, Beierlein Milena, Belleville Erik, Untch Michael, Thill Marc, Tesch Hans, Ditsch Nina, Lux Michael P, Aktas Bahriye, Banys-Paluchowski Maggie, Kolberg-Liedtke Cornelia, Hartkopf Andreas D, Wöckel Achim, Kolberg Hans-Christian, Harbeck Nadia, Stickeler Elmar
Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
Onkologie Aschaffenburg, Aschaffenburg, Germany.
Geburtshilfe Frauenheilkd. 2023 Mar 9;83(3):289-298. doi: 10.1055/a-2018-9053. eCollection 2023 Mar.
The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.
近年来，由于帕博利珠单抗、奥拉帕利和阿贝西利的引入，早期乳腺癌患者的治疗发生了变化。这些药物以及其他具有相同活性成分类别的药物目前正在针对各种适应症进行试验。这篇综述文章总结了在ESMO 2022等主要会议上发表或最近在国际期刊上发表的最新结果。这包括关于新发现的乳腺癌基因的报告、阿替利珠单抗在HER2阳性患者新辅助治疗中的应用、APHINITY研究的长期数据，以及术前瘤周应用局部麻醉剂如何影响预后。我们还展示了来自ADAPT研究的关于动态Ki-67的可靠数据。
